Genelux Corp. manufactures and markets drugs and virus strains solutions. The company is headquartered in Westlake Village, California and currently employs 24 full-time employees. The company went IPO on 2023-01-26. The firm is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Follow-Up Questions
Who is the CEO of Genelux Corp?
Mr. Thomas Zindrick is the Chairman of the Board of Genelux Corp, joining the firm since 2014.
What is the price performance of GNLX stock?
The current price of GNLX is $5.75, it has increased 0.52% in the last trading day.
What are the primary business themes or industries for Genelux Corp?
Genelux Corp belongs to Biotechnology industry and the sector is Health Care
What is Genelux Corp market cap?
Genelux Corp's current market cap is $217.1M
Is Genelux Corp a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Genelux Corp, including 2 strong buy, 8 buy, 1 hold, 0 sell, and 2 strong sell
